Ascelia Pharma AB (7ZA) Price & Analysis

Compare

2 Followers

7ZA Stock Chart & Stats

€0.29

>-€0.01(-1.21%)

At close: Jan 08 4:00 PM EST

€0.29

>-€0.01(-1.21%)

Day’s Range― - ―

52-Week Range€0.17 - €0.47

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€38.12M

Enterprise Value€337.50M

Total Cash (Recent Filing)€49.86M

Total Debt (Recent Filing)€1.04M

Price to Earnings (P/E)―

Beta0.60

Next Earnings

May 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding126,868,800

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)3.67

Price to Sales (P/S)0.00

P/FCF Ratio-5.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Orphan-drug Niche FocusAscelia's focus on orphan oncology indications and a lead program addressing imaging for patients with impaired kidney function positions it in a high-unmet-need niche. Orphan programs often benefit from regulatory incentives, concentrated patient populations and clearer commercial pathways versus broad indications.

Low LeverageVery low reported leverage reduces near-term fixed-cost pressure from interest and refinancing, giving the company financial flexibility. This structural balance-sheet strength supports R&D continuity and negotiating power when arranging future financing or partnerships.

Improving Cash-burn TrendMaterial reduction in annual cash burn versus prior years indicates better cost control or streamlined development spending. A sustained downward burn trend lengthens runway and reduces probability of imminent dilutive financings, improving the odds of advancing clinical milestones.

Bears Say

Pre-revenue ProfileThe company has no reported revenue, meaning commercial validation and recurring cash inflows are absent. Long dependence on clinical and regulatory milestones makes sustained operations contingent on successful trials or external funding rather than organic cash generation.

Persistent Negative Cash FlowConsistent negative operating and free cash flow requires repeated access to capital markets or partners. Over a multi-quarter horizon this raises dilution risk and execution uncertainty if financing terms deteriorate or fundraising windows narrow.

Equity ErosionSubstantial decline in shareholders' equity over several years reflects accumulated losses and capital consumption. This weakens the balance-sheet buffer, reduces resilience to clinical setbacks, and increases pressure to secure financing under potentially adverse terms.

Ascelia Pharma AB News

Ascelia Pharma’s Orviglance NDA Accepted by FDA as Cash Runway Extends Beyond 2026 Decision

Ascelia Pharma AB ( ($SE:ACE) ) has provided an announcement. Ascelia Pharma reported that the US Food and...

20d ago

Ascelia Pharma Deputy CEO and CFO Julie Waras Brogren to Depart for New CEO Role

The latest announcement is out from Ascelia Pharma AB ( ($SE:ACE) ). Ascelia Pharma has announced that Deputy...

1M ago

Ascelia Pharma Appoints Nomination Committee Ahead of 2026 AGM

Ascelia Pharma AB ( ($SE:ACE) ) has issued an announcement. Ascelia Pharma has appointed its Nomination Committee for...

2M ago

Ascelia Pharma Adjusts Share Structure Following Share Saving Program

The latest announcement is out from Ascelia Pharma AB ( ($SE:ACE) ). Ascelia Pharma AB announced a change...

3M ago

Ascelia Pharma Converts Series C Shares to Ordinary Shares for Incentive Program

An announcement from Ascelia Pharma AB ( ($SE:ACE) ) is now available. Ascelia Pharma’s Board of Directors has...

3M ago

FDA Accepts Ascelia Pharma’s Orviglance NDA for Review

Ascelia Pharma AB ( ($SE:ACE) ) has provided an update. Ascelia Pharma announced that the FDA has accepted...

3M ago

Ascelia Pharma Files Patent for Orviglance, Enhancing Market Protection

Ascelia Pharma AB ( ($SE:ACE) ) just unveiled an announcement. Ascelia Pharma has filed a new patent application...

4M ago

Ascelia Pharma Advances Orviglance with FDA Submission and Financial Strengthening

Ascelia Pharma AB ( ($SE:ACE) ) has shared an update. Ascelia Pharma AB has submitted a New Drug...

4M ago

Ascelia Pharma Strengthens Leadership Team for Future Growth

An update from Ascelia Pharma AB ( ($SE:ACE) ) is now available. Ascelia Pharma AB has announced significant...

4M ago

Ascelia Pharma Completes SEK 30 Million Directed Share Issue

Ascelia Pharma AB ( ($SE:ACE) ) has shared an announcement. Ascelia Pharma AB has successfully completed a directed...

5M ago

7ZA FAQ

What was Ascelia Pharma AB’s price range in the past 12 months?

Ascelia Pharma AB lowest stock price was €0.17 and its highest was €0.47 in the past 12 months.

What is Ascelia Pharma AB’s market cap?

Ascelia Pharma AB’s market cap is €38.12M.

When is Ascelia Pharma AB’s upcoming earnings report date?

Ascelia Pharma AB’s upcoming earnings report date is May 14, 2026 which is in 79 days.

How were Ascelia Pharma AB’s earnings last quarter?

Ascelia Pharma AB released its earnings results on Feb 05, 2026. The company reported -€0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.012.

Is Ascelia Pharma AB overvalued?

According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ascelia Pharma AB pay dividends?

Ascelia Pharma AB does not currently pay dividends.

What is Ascelia Pharma AB’s EPS estimate?

Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ascelia Pharma AB have?

Ascelia Pharma AB has 126,868,800 shares outstanding.

What happened to Ascelia Pharma AB’s price movement after its last earnings report?

Ascelia Pharma AB reported an EPS of -€0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -35.075%.

Which hedge fund is a major shareholder of Ascelia Pharma AB?

Currently, no hedge funds are holding shares in DE:7ZA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.